COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
13 hedge funds and large institutions have $478K invested in COSCIENS Biopharma Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 5 closing their positions.
7% less funds holding
Funds holding: 14 → 13 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
53% less capital invested
Capital invested by funds: $1.02M → $478K (-$545K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
+$76.9K |
| 2 |
Jane Street
New York
|
+$51.3K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$38.4K |
| 4 |
JP Morgan Chase
New York
|
+$38.4K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$25.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$745K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$26K |
| 3 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$20K |
| 4 |
Goldman Sachs
New York
|
-$18K |
| 5 |
AAM
Azzad Asset Management
Falls Church,
Virginia
|
-$14.3K |
CSCI Hedge Fund Activity: Q3 2014 in Review
13 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q3 2014, worth a combined $478K — down 53% from $1.02M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CSCI and 4 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.
The largest buyer was Nine Chapters Capital Management, adding an estimated $76.9K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $745K sold.
- 13 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q3 2014, down from 14 in Q2 2014.
- Funds reported $478K of COSCIENS Biopharma Inc. Common Stock stock for Q3 2014, down 53% quarter-over-quarter.
- 4 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q3 2014 and 5 closed out, a net change of -1 holder.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q3 2014 was Nine Chapters Capital Management, an estimated $76.9K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q3 2014 was Renaissance Technologies, an estimated $745K sold.
Based on aggregated 13F filings for Q3 2014.